Diversify Advisory Services LLC Reduces Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Diversify Advisory Services LLC reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 22.6% in the 4th quarter, Holdings Channel reports. The firm owned 40,128 shares of the company’s stock after selling 11,700 shares during the period. Diversify Advisory Services LLC’s holdings in Hims & Hers Health were worth $1,020,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after buying an additional 2,152 shares during the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the period. CWM LLC grew its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Quarry LP increased its stake in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

NYSE HIMS opened at $27.80 on Tuesday. The business has a 50 day moving average price of $27.68 and a 200 day moving average price of $21.91. The company has a market capitalization of $6.07 billion, a P/E ratio of 63.19 and a beta of 1.31. Hims & Hers Health, Inc. has a 1-year low of $8.14 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) EPS. The business’s revenue was up 77.1% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HIMS. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Canaccord Genuity Group upped their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $25.13.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the sale, the chief financial officer now owns 118,077 shares in the company, valued at approximately $2,885,801.88. This trade represents a 8.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,072,708 shares of company stock worth $28,940,323. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.